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Summary Growth of the EGF receptor-expressing non-small-cell lung carcinoma cell line H125 seems to be at least partially driven by
autocrine activation of the resident EGF receptors. Thus, the possibility of an EGF receptor-directed antiproliferative treatment was investigated
in vitro using a monoclonal antibody (cxEGFR ior egf/r3) against the human EGF receptor and gangliosides which are known to possess
antiproliferative and anti-tyrosine kinase activity. The moderate growth-inhibitory effect of aEGFR ior egf/r3 was strongly potentiated by the
addition of monosialoganglioside GM3 Likewise, the combination of aEGFR ior egf/r3 and GM3 inhibited EGF receptor autophosphorylation
activity in Hi 25 cells more strongly than either agent alone. A synergistic inhibition of EGF receptor autophosphorylation by aEGFR ior egf/r3
and GM3 was also observed in the human epidermoid carcinoma cell line A431. In both cell lines, the inhibition of EGF receptor
autophosphorylation by GM3 was prevented by pretreatment of the cells with pervanadate, a potent inhibitor of protein tyrosine phosphatases
(PTPases). Also, GM3 accelerated EGF receptor dephosphorylation in isolated A431 cell membranes. These findings indicate that GM3 has the
capacity to activate EGF receptor-directed PTPase activity and suggest a novel possible mechanism for the regulation of cellular PTPases.
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Epidermal growth factor (EGF) is a 6-kDa peptide (Cohen and
Carpenter, 1975) that binds to a 170-kDa transmembrane receptor
(EGFR) with intrinsic tyrosine kinase activity (Ullrich and
Schlessinger, 1990). Ligand-induced receptor dimerization and
autophosphorylation are essential subsequent steps for the initia-
tion of intracellular events, which ultimately lead to EGF-induced
cell division. The autophosphorylation of the EGFR is rapidly
reverted by cellular PTPases, the identity of which remains to be
established (Swarup et al, 1982; Charbonneau and Tonks, 1992;
Faure et al, 1992; Pot and Dixon, 1992; Bohmer et al, 1993, 1995).
Apparently, different PTPases, including those of cytosolic or
transmembrane type, have the capacity to dephosphorylate
autophosphorylated EGFR (Hashimoto et al, 1992; Lammers et al,
1993). Recently, the SH2-domain PTPase, PTP1C, has been
shown to associate with the EGFR and to dephosphorylate it in
A431 cells and in 293 cells overexpressing PTP1C and EGFR
(Tomic et al, 1995). Receptor dephosphorylation is considered a
major mechanism of negative regulation of receptor activity.
A relation between the EGF/EGFR system and malignant
cell transformation has been well established in experimental
systems (Downward et al, 1984; Hayman et al, 1985; Derynck et
al, 1987; Di Fiore et al, 1987; Velu et al, 1987). More importantly,
EGFR expression in human breast tumours has been correlated
with a poor prognosis (Perez et al, 1984; Sainsbury et al, 1985;
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Macias et al, 1986, 1987a, b; Klijn et al, 1992), and a link between
EGFR activity and the malignant process has also been suggested
for a number of other epithelial tumours, including non-small-cell
lung cancer (NSCLC) (Khazaie et al, 1993; Modjtahedi and Dean,
1994; Fontanini et al, 1995). Therefore, the evaluation of the
EGF/EGFR system as a potential target for tumour therapy is
highly warranted (Baselga and Mendelsohn, 1994a; Modjtahedi
and Dean, 1994). Different strategies have been employed to block
EGFR signalling. Paradoxically, EGF itself can be inhibitory for
cell growth under certain conditions (Barnes, 1982; Lombardero et
al, 1986; Kamata et al, 1986). Although the exact mechanism of
this effect remains elusive, this principle was used successfully in a
pilot clinical trial for treatment of skin epidermoid carcinoma
(Fonseca et al, 1988). Attempts to design on a peptide basis EGF
antagonists that block EGF binding to its receptor have up to now
had little success (Groenen et al, 1994). Alternatively, anti-receptor
antibodies have been generated in a number of laboratories and
investigated with respect to a potential therapeutical application
(Mueller et al, 1991; Fernandez et al, 1992; Fong et al, 1992;
Modjtahedi et al, 1993; Reins et al, 1993; for a review see Baselga
and Mendelsohn, 1994b). Although some of the clinical data
obtained so far are encouraging, the general impression emerges
from these studies that antibody treatment alone will not be suffi-
cient to combat EGFR-driven tumours, but will need combination
with further antiproliferative agents (Baselga and Mendelsohn,
1994b). A further strategy to block EGFR signalling would be the
specific inhibition of receptor tyrosine kinase activity (Gibbs and
Oliff, 1994; Levitzki and Gazit, 1995). Recent efforts to obtain
synthetic EGFR kinase inhibitors yielded quite potent and specific
compounds, which might lead to useful pharmacological agents in
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the future. Among various naturally occurring tyrosine kinase
inhibitors, the ganglioside, GM3, has been reported to attenuate
EGFR signalling (Bremer et al, 1986; Hanai et al, 1988; Weis and
Davis, 1990; Zhou et al, 1994); however, the mechanism of this
effect is not well understood. Gangliosides are oflow general toxi-
city and often have pronounced antiproliferative and differentia-
tion-inducing properties (Hakomori, 1993; Svennerholm, 1994). In
the current study, we therefore explored the possibility that a
combined action ofganglioside GM3 and an anti-EGF receptor anti-
body, designated ocEGFR ioregf/r3 (Fernandez et al, 1992), would
lead to a more pronounced inhibition ofthe proliferation ofEGFR-
expressing tumour cell lines. We demonstrate a synergistic effect
of xEGFR ior egf/r3 and GM3 on EGFR signalling activity and
growth in H125 human NSCLC cells. Furthermore, our data
suggest that activation ofEGFR-directed PTPases by GM3 might, at
least in part, constitute the mechanism underlying the inhibition of
EGFR activity by GM .
MATERIALS AND METHODS
Cells and reagents
Eleven different cell lines derived from human lung tumours were
generously provided by Drs Gazdar (Dallas, TX, USA) and Bergh
(Uppsala, Sweden). NCI H125 and NCI H23 originate from adeno-
carcinoma (Gazdar et al, 1980; Carney et al, 1985); U1810, NCI
H157 and NCI H661 originate from large-cell carcinoma (Bergh et
al, 1982, 1985; Carney et al, 1985); U1752 originates from a squa-
mous cell carcinoma (Bergh et al, 1981); and NCI H82, U1285,
U1690, U1906 and U2020 from small-cell carcinomas of the lung
(Carney et al, 1985, Bergh et al, 1982, 1985). All lung cancer cell
lines were grown in RPMI-1640 medium (Seromed, Berlin)
supplemented with 10% fetal bovine serum (Gibco Life
Technologies), 100 U ml penicillin and 100 U ml streptomycin
and were kept at 37C in humidified atmosphere containing 5%
carbon dioxide. A431 epidermoid carcinoma cells (CRL 1555)
were obtained from the American Type Culture Collection
(Rockville, USA). A431 cell culture and isolation of a membrane
fraction were performed as described (Tomic et al, 1995).
Human recombinant EGF was provided by the Center of
Genetic Engineering and Biotechnology of Havana, Cuba. The
monoclonal anti-EGF receptor antibody, ocEGFR ior egf/r3, was
generated at the Center of Molecular Immunology of Havana as
described earlier (Fernandez et al, 1992). The antibody used in this
study was purified from mouse ascites by protein A affinity chro-
matography. A CD3-specific monoclonal antibody of the same
isotype (IgG 2A), designated 'ior t3' was also generated at the
Center of Molecular Immunology of Havana. The monoclonal
anti-EGF receptor antibody 425 (Rodeck et al, 1987), designated
'aEGFR mab425', was kindly provided by Dr A Luckenbach
(E Merck, Darmstadt, Germany). A monoclonal antibody against
the C-terminus ofhuman EGF receptor was obtained from Zymed
(South San Francisco, USA) and is designated oaEGFR-CT. GM3
gangloside was purified from sheep spleen as described by
Svennerholm (1973). The purity of the preparation was deter-
mined by high-performance liquid chromatography (HPLC) and
was at least 95%. The structure of the ganglioside was confirmed
by FAB mass spectrometry. De-N-acetyl-GM3 was obtained from
GM3 as described by Nores et al (1989). The gangliosides were
dissolved in phosphate-buffered saline (PBS) by sonication and
then passed through a0.2-gM sterile filter.
The specific EGFR-blocking tyrphostins, AG1478 and
AG1517, were kindly provided by Drs Gazit and Levitzki
(Jerusalem, Israel), (Fry et al, 1994; Osherov and Levitzki, 1994;
Levitzki and Gazit, 1995). They were dissolved in dimethyl
sulphoxide (DMSO); for application in cell culture, the final
DMSO concentration in the assays was < 0.1%, only DMSO ofthe
same concentration was included in the corresponding controls.
Pervanadate was prepared from sodium orthovanadate stocks and
hydrogen peroxide as described by Pumiglia et al (1992).
EGF receptor assay
The amount of EGF receptor in the various lung cancer cell lines
was measured as previously described (Macias et al, 1986).
Briefly, cells were seeded in 24-well plates (Costar) at 5 x 105
cells per well. On the next day, the culture medium was removed
and the plates were washed three times with PBS containing 10
mm magnesium chloride and 10 mm calcium chloride. Then the
cells were incubated with approximately 105 c.p.m. of ['25]EGF
(150-200jCijig-') in the absence or presence ofdifferent concen-
trations of unlabelled EGF in 0.5 ml of 10 mm Tris-HCl, pH 7.4,
10 mm magnesium chloride, 0.1% bovine serum albumin (BSA)
(binding buffer) for 1 h at room temperature. Thereafter, the cells
were washed with binding buffer and the bound radioactivity was
recovered with 100 jil of 1M sodium hydroxide and measured in a
gamma counter. Non-specific binding was estimated in the pres-
ence of 1000 ng ml-' EGF. Data were analysed according to
Scatchard's method (Scatchard, 1949).
Growth assay
H125 cells were seeded in 24-well plates at 5 x 104 cells per well.
One day later, the medium was replaced with RPMI medium
containing 2% fetal bovine serum (FBS) and the desired effectors.
This medium was changed every 2 days including renewal of
effectors. At the desired time points, cell layers were washed with
PBS and dissolved with 300 jil of 1.5 M sodium hydroxide for I h
at room temperature, and the total amount of protein was deter-
mined. Alternatively, cells were labelled with [3H]thymidine
(1 ,uCi ml', 2 jiM thymidine) for 18-24 h. Cell protein content and
[3H]thymidine incorporation were linearly correlated under stan-
dard growth conditions of H125 cells.
EGFR autophosphorylation and dephosphorylation
assays
Subconfluent cultures of H125 or A431 cells in six-well plates
(Falcon) were treated overnight with serum-free medium. The
medium was changed and the desired agents were added as
described in the figure legends. Then the cells were stimulated
with 1 jg ml-' EGF for 1 min at room temperature or left unstimu-
lated. Cell extracts were prepared as described (Tomic et al, 1995),
using 200 jil of lysis buffer per well. About 20 jig or 5 jig of
protein per lane of H125 or A431 cell extract, respectively, was
analysed by sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and immunoblotting with anti-phospho-
tyrosine antibodies (RC20-peroxidase conjugate, Transduction
Laboratories) and ECL (Amersham) detection. Quantification was
performed by densitometric scanning of the films and analysis
using the program NIH image 1.52. To evaluate the amount of
EGFR analysed, the blots were stripped and reprobed with the
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Table 1 EGF receptor expression in human lung cancer cell lines as
revealed by a radio receptor assay
Cell line Amount of receptors Dissociation constants
(sites per cell) Kd (nM)
NSCLCb
H125 (ADC) 2.1±0.20 x 105 1.7±0.33
H23 (ADC) 2.9±1.90 x 104 6.0±1.40
H661 (LCC)
H157 (LCC) 2.4±0.45 x 105 1.2±0.09
U1810 (LCC) 7.0±2.80 x 103 1.4±0.56
U1752 (SQC) 1.3±0.26 x 105 1.7±0.26
SCLC
H82
U1285
U1690 2.5±1.44 x 104 2.5±1.30
U1906
U2020
a[1251]EGF binding was measured by a standard technique as described under
Materials and methods, and the data were analysed according to Scatchard
(1949). bNSCLC, non-small cell lung carcinoma; SCLC, small-cell lung
carcinoma; ADC, lung adenocarcinoma; LLC, lung large-cell carcinoma;
SQC, squamos cell carcinoma.
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taken at different time points and mixed with SDS-PAGE sample
buffer. The samples were subjected to SDS-PAGE, the gels were
stained and dried and the radioactivity in the EGF receptor band
was quantified using a GS250 Molecular lmager (Bio-Rad,
Munich, Germany).
RESULTS
EGF receptor expression in lung cancer cell lines
In order to choose a suitable in vitro system for evaluation of
EGFR-directed antiproliferative treatments, different lung cancer
cell lines were compared for expression of EGFR using a binding
assay with [1251] EGF. The results are summarized in Table 1.
Except H661 cells, all other NSCLC cell lines tested exhibited
moderate to high levels of EGFR expression. Among the SCLC
cell lines tested, only U1690 revealed EGFR expression as
detectable with this assay. Therefore, most ofthe furtherinvestiga-
tion was performed with H125 cells, which express 2.1 x 105
EGFR sites per cell.
Growth modulation of H125 cells by EGF and EGFR-
specific tyrosine kinase inhibitors
When H125 cells were treated with EGF at 10, 100 and 1000 ng
ml-' in the presence of 1% fetal calf serum (FCS), the growth rate
increased in a dose-dependent manner (Figure 1), albeit to a
moderate extent. The relatively low potency ofexogenously added
EGF might be due to the constitutive presence of endogenous
TGFa, which is known to be expressed in H125 cells (Soderdahl
et al, 1988). In order to test whether an autocrine pathway
involving the EGFR contributes to the growth of these cells, the
effect of a recently discovered highly specific EGFR tyrosine
kinase inhibitor, designated AG1478 (Osherov and Levitzki, 1994;
Levitzki and Gazit, 1995), was tested. H125 cells were cultured in
the absence orpresence ofAG1478. AG1478 treatmenteffectively
inhibited stimulation of EGFR autophosphorylation by exoge-
nously added EGF (Figure 2A). Culturing H125 cells in the pres-
ence of AG1478 and in the absence of exogenously added EGF
reduced the growth rate of the cells to about 69% in a concentra-
tion as low as 0.1 ,IM and to 3% at I ,UM (Figure 2B). In contrast,
H661 NSCLC cells, which have undetectable EGFR levels (Table
1), are resistant to treatment with AG1468, indicating that the
effect of H125 is specific and non-toxic. Identical results were
obtained with another EGFR tyrosine kinase inhibitor, AG1517
[PD 153035 (Fry et al, 1994)] (Figure 2B). These findings suggest
a partial dependence of H125 cell growth on EGFR signalling
even in the absence ofexogenously added EGF.
Growth modulation of H125 cells by anti-EGF receptor
antibody aEGFR ioregf/r3and ganglioside GM3
The previously described anti-EGF receptor antibody, aEGFR ior
egf/r3 (Fernandez et al, 1992), is known to inhibit EGF binding
and EGFR signalling, and we wished to explore its potential
usefulness for growth inhibition ofEGFR-expressing NSCLC. As
shown in Figure 3A, aEGFR ior egf/r3 inhibited the growth of
H125 cells. Whereas 10 ,ug ml-' aEGFR ior egf/r3 used in this
assay only had a small inhibitory effect, the cell growth rate was
reduced to 50% and 41% at 30 and 100 jg ml-' respectively. The
addition of an unrelated murine monoclonal antibody (axCD3 ior
t-3) with identical isotype had no effect on proliferation of H125
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Figure 2 Effect of the specific EGF receptor tyrosine kinase blockers on
EGFR autophosphorylation and growth of H125 cells. (A) Serum-deprived
subconfluent cultures of H125 cells were treated with different concentrations
of AG1478 for 2 h. Thereafter, the cells were stimulated with EGF (or not, as
indicated), cell extracts were prepared and the EGFR phosphorylation was
analysed by SDS-PAGE and immunoblotting with antiphosphotyrosine
antibodies. (B) H125 cells or the EGF receptor-negative NSCLC H661 cells
were cultured for 3 days in the absence or presence of different
concentrations of AG1478 or AG1517 as indicated and then [3H]thymidine
incorporation was measured. Data points are the means + s.d. of triplicates
calculated as a percentage of control
cells. Similar results were obtained with other EGFR-positive cell
lines, such as H157 and U1752 (data not shown).
We then tested the possibility of enhancing the antiproliferative
effect of ocEGFR ior egf/r3 by simultaneous addition of ganglio-
side GM3. GM3 at 0.5 and 5gM had little effect on H125 cell growth
(Figure 4A) and inhibited growth partially at 20 ,ug ml. However,
when combined with ocEGFR ior egf/r3, 5 g1M ganglioside, which
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Figure 3 Effect of the monoclonal anti-EGF receptor antibody aEGFR ior
egf/r3on growth and EGFR autophosphorylation of H125 cells. (A) H125
cells were cultured for 7 days in the absence or presence of different
concentrations of the monoclonal antibodies as indicated. Thereafter, the
total amount of cells was measured by protein determination. Data points are
means + s.d. of triplicates calculated as a percentage of control. (B) Serum-
deprived subconfluent H125 cells were treated with different concentrations
of ioregf/r3 as indicated for 2 h. Thereafter, the cells were stimulated with
EGF as indicated, extracted and the EGFR phosphorylation was analysed by
SDS-PAGE and immunoblotting with antiphosphotyrosine antibodies
alone was ineffective, potentiated the inhibitory effect produced
by ocEGFR ior egf/r3 and reduced growth to about 12% ofcontrol.
GM3 (20 gIM) plus ocEGFR ior egf/r3 almost completely inhibited
cell growth and partially resulted in cell death. This cytotoxic
effect was strictly mediated by EGFR, because the growth of the
EGFR-negative cell line H661 was not significantly affected by
the combination of ocEGFR ior egf/r3 and 5 g,M GM3 (Figure 4B).
Also, the synergistic growth inhibition was specific for GM3, since
De-N-acetylGM3 at 20 gM alone had only a slight effect on H125
cell growth and did not further enhance the growth inhibition
exerted by ocEGFR ior egf/r3 (Figure 4A). A very similar syner-
gistic growth inhibition of H125 cells was also observed with the
combination of another anti-EGFR antibody, otEGFR mab425,
and GM3. Also, ocEGFR mab425 and GM3 synergistically inhibited
growth ofthe EGFR-expressing NSCLC cell line, Ul752 (data not
shown).
Effect of the anti-EGF receptor antibody, ocEGFR ior
egf/r3, and ganglioside GM3 on EGFR signalling activity
To evaluate whether the enhanced growth inhibition ofHI25 cells
exerted by ocEGFR ior egf/r3 in the presence of the ganglioside
GM3 is mediated by an enhanced inhibition of EGFR signalling
activity, the effect of both agents on EGFR autophosphorylation
was investigated. Intact H125 cells were pretreated with ocEGFR
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Figure 4 Effect of the combination of ganglioside GM3 and the monoclonal anti-EGF receptor antibody aEGFRioregf/r3 on EGFR autophosphorylation and
growth of H125 cells. (A) H125 cells were treated without ganglioside (control) O-1, or with 0.5 ,UM GM3 °I1, 5 ,UM GM3 E, 20 ,UM GM3 *, 20 ,UM De-N-acetyl GM3
in the presence or absence of anti-EGF receptor antibody aEGFRioregf/r3 as indicated for 7 days. Thereafter, the total amount of cells was measured as
described in Figure 1. Data points are the means ± s.d. of triplicates calculated as a percentage of control. (B) the same assay as in A with the EGF receptor-
negative NSCLC cell line H661. (C) Serum-deprived subconfluent cultures of H125 cells were treated with ganglioside GM3 or the anti-EGF receptor antibody
aEGFRior egf/r3 or the combination of both as indicated for 2 h. Thereafter, the cells were stimulated with EGF or not as indicated, extracted and the EGFR
phosphorylation was analysed by SDS-PAGE and immunoblotting with antiphosphotyrosine antibodies (upper panel). The numbers underneath the lanes
represent the percentage of the autophosphorylation signal compared with the control in the absence of GM3 or aEGFRior egf/r3, as revealed by densitometric
scanning. The blot was stripped and reprobed with anti-EGFR-CT antibodies to verify that similar amounts of receptor are present in the individual lanes (lower
panel). (D) H125 cells were treated for 30 min with pervanadate or not (as indicated) and subsequently with GM3 at different concentrations. Then, EGF
receptors were immunoprecipitated from cell extracts and the tyrosine phosphorylation state was evaluated by immunoblotting as in C
ior egf/r3, GM3 or both. Thereafter, the cells were stimulated with
EGF, lysed and the extent of EGFR autophosphorylation was
measured by immunoblotting with anti-phosphotyrosine anti-
bodies. EGFR autophosphorylation was inhibited by axEGFR ior
egf/r3 in a dose-dependent manner (Figure 3B). Treatment of the
cells with 50 ,ug mll aEGFR ior egf/r3 resulted in a reduction of
EGFR autophosphorylation to 43% (Figure 4C, upper panel). GM3
treatment of the cells alone had little effect at 20-50 gM GM3 and
required as much as 200 gM GM3 to obtain a reduction in receptor
autophosphorylation to 47%. This finding is in accordance with
earlier observations, indicating that rather high concentrations of
GM3 are required to inhibit EGFR signalling acitivity in A431 cells
(Zhou et al, 1994). Combined treatment of the cells with axEGFR
ioregf/r3 and GM3 drastically reduced EGFR autophosphorylation,
already at 20 gM GM3 to 28% and down to 17% at 200 gM. The
level of EGFR protein was essentially unaffected by the different
treatments (Figure 4C, lower panel). Thus, the combined action of
xEGFR ior egf/r3 and GM3 leads to an inhibition of EGFR
autophosphorylation, which is qualitatively matching the observed
synergistic inhibition ofH125 cell growth.
For comparison, the effects of GM3 and aEGFR ior egf/r3 on
EGFR autophosphorylation in A431 human epidermoid carcinoma
cells were investigated. As shown in Figure 5A, similarly to H125
cells, combined treatment of A431 cells with GM3 and aEGFR ior
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egf/r3 inhibits EGFR autophosphorylation. In comparison with
H125 cells, xEGFR ior egf/r3 alone was less effective, and GM3
was more effective in inhibiting EGFR activity in A431 cells. The
combined inhibition of receptor autophosphorylation by both
agents was more pronounced in A431 than in H125 cells (Figures
4B and 5A).
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Figure 5 Synergistic inhibition of EGF receptor autophosphorylation by
ganglioside GM3 and anti-EGF receptor antibody aEGFR ioregf/r3 in A431
cells. (A) Serum-deprived subconfluent cultures of A431 cells were treated
with ganglioside GM3 and ior egf/r3 as indicated for 2 h. Thereafter, the cells
were stimulated with EGF as indicated and cell extracts were analysed by
SDS-PAGE and immunoblotting with antiphosphotyrosine antibodies. (B) The
membrane blot was stripped and reprobed with aEGFR-CT antibodies as
described in Materials and methods. (C and D) The same experiment as in A
and B; however the cells were incubated with pervanadate for 30 min before
EGF stimulation
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Figure 6 Effect of ganglioside GM3 on EGF receptor dephosphorylation in
A431 cell membranes. A431 cell membranes were incubated with or without
60 itg ml-' GM3 as indicated and EGF. EGFR autophosphorylation was
initiated by addition of [y32P]ATP and allowed to proceed for 10 min on ice.
Thereafter, the reaction was quenched by addition of EDTA and receptor
dephosphorylation was monitored by analysing aliquots corresponding to 10
pg of membrane protein at the indicated time points by SDS-PAGE and
autoradiography for the EGF receptor phosphate content. The relative
radioactivity in the receptor bands was quantified with a Phosphoimager. (A)
Autoradiograph; (B) time course of receptor dephosphorylation as obtained
by Phosphorimager analysis of the relative radioactivity in the EGF receptor
band. The depicted experiment is one of three with identical results
Interestingly, when the A431 cell treatment was performed in the
presence ofpervanadate, a potent inhibitorofPTPases (Pumiglia et
al, 1992), the inhibition of EGFR autophosphorylation by GM3 as
well as the synergistic inhibition of EGFR autophosphorylation by
GM3 and xEGFR ior egf/r3, was abolished (Figure SC). Also, GM3-
mediated inhibition ofEGFR autophosphorylation in H125 cells is
prevented by pervanadate treatment (Figure 4D). These findings
indicate that activation of EGFR-directed PTPases rather than
direct tyrosine kinase inhibition by GM3 might at least contribute to
the observed attenuation of EGFR autophosphorylation. To test
directly whether GM3 has the capacity to activate EGFR-directed
PTPase activity, in vitro PTPase assays employing A431 cell
membranes were carried out. Membranes were pretreated with GM3
or vehicle, the EGFR was stimulated and autophosphorylation
was allowed to occur in the presence of [y32P]ATP. The autophos-
phorylation was quenched by addition of EDTA, and EGFR
dephosphorylation by the endogenous PTPases was monitored by
analysis of the receptor phosphorylation state at different time
points thereafter. As shown in Figure 6, EGFR dephosphorylation
is clearly accelerated in the presence of60 [tM GM3.
DISCUSSION
Lung cancer cells, in particular NSCLC, frequently express
EGFR. Thus, although the prognostic significance of EGFR
expression in lung carcinoma is currently controversial
(Modjtahedi and Dean, 1994), the EGFR might present a target for
antiproliferative treatment. We compared a limited number oflung
carcinoma cells for expression ofEGFR by a ligand-binding assay.
In accordance with previous observations, five out of six NSCLC
cell lines contained measurable levels of EGFR sites per cell,
while only one out of five SCLC cell lines was EGFR positive.
HI25, an NSCLC line with about 2 x 105 EGF receptors per cell,
was chosen to investigate the antiproliferative potency of an
EGFR-blocking monclonal antibody (ocEGFR ior egf/r3) towards
NSCLC. Apparently, the growth of this cell line is at least partly
dependent on autocrine activation ofthe EGFR, since: (1) the cells
are known to express TGFoc (Soderdahl et al, 1988) in addition to
EGFR; (2) the cells respond only moderately to exogenous EGF;
and (3) most importantly, the cells are growth inhibited by very
low doses of highly specific EGFR tyrosine kinase inhibitors,
whereas NSCLC cells not expressing EGFR were completely
refractory to the drugs. The anti-EGF receptor antibody, aEGFR
ior egf/r3, reduced the growth of H125 cells under the same
culture conditions to 41%, without cytotoxic effect. These results
match well with those from ongoing in vivo studies with oxEGFR
ior egf/r3. No relevant toxic effects have been found; however,
the cytostatic effects on the tumours observed so far are only
moderate (unpublished data). Similar results have been reported
for other studies employing EGFR-blocking antibodies (Baselga
and Mendelsohn, 1994b), suggesting the need to combine this
treatment with another antiproliferative principle. We therefore
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investigated the effect of a combined antiproliferative cell treat-
ment with the anti-EGF receptor antibody, cEGFRior egf/r3, and
gangliosides, again using the NSCLC line H125 as a target.
Indeed, ganglioside GM3 (but not De-N-acetlylGM3) was found
greatly to potentiate the effect of axEGFR ior egf/r3 on the growth
ofthese EGFR-expressing cells leading to almost complete growth
arrest and cytotoxicity. This effect was dependent on the presence
of EGFR, since growth of an NSCLC line lacking EGFR expres-
sion was completely unaffected by the combined treatment.
Synergistic growth inhibition was also observed using another
NSCLC cell line (U1752) as target or using the combination of
another anti-EGFR antibody (ocEGFR mab425) and GM3 for the
treatment, suggesting that the observed synergism is general.
Experiments are underway to analyse further this new cytostatic
concept in experimental tumours in vivo. A similar synergistic
growth inhibition by a combination of an anti-EGFR antibody and
a synthetic tyrosine kinase inhibitor has been observed for a squa-
mous cell carcinoma by Yoneda et al (1991).
When we compared the effect of various treatments of H125
cells on cell growth with that on EGFR autophosphorylation
activity, we observed an overall correlation of the inhibitory
effects. Cell growth was blocked by specific EGFR tyrosine
kinase inhibitors, the anti-EGF receptor antibody ocEGFR ior
egf/r3 inhibited receptor autophosphorylation and the combination
of axEGFR ior egj/r3 and GM3 had a stronger effect on EGFR
autophosphorylation than either agent alone. Taken together, these
correlations suggest that the observed EGFR tyrosine kinase inhi-
bition is causally related to growth inhibition. Some differences
in the dose - response characteristics for growth inhibition and
kinase attenuation were, however, observed. Most notably, the
combined inhibition by ocEGFR ior egf/r3 and GM3 was less
pronounced on the level of H125 cell EGFR autophosphorylation
than on the level of cell growth. These quantitative differences
might be a result of the somewhat different treatment and assay
schedules for the two parameters. It is, however, currently not
possible to exclude additional effects of the agents used on other
cellular systems contributing to the observed growth inhibition.
Growth factor receptor signalling activity at the level ofreceptor
autophosphorylation is the net result ofthe action ofreceptor PTK
and opposing PTPases. We therefore investigated whether the
synergistic inhibitory effect of xEGFR ior egf/r3 and GM3 on the
EGFR autophosphorylation involved merely tyrosine kinase inhi-
bition or possibly also effects on the EGFR-directed PTPase(s).
Interestingly, the attenuation of EGFR autophosphorylation by
GM3 in H125 cells and in A431 cells is abrogated by pretreatment
of the cells with the PTPase inhibitor, pervanadate. Furthermore,
GM3 has the capacity to activate EGFR dephosphorylation in A431
cell membranes in vitro. Thus, activation of EGFR-directed
PTPases by GM3 seems to be involved in the attenuation of EGFR
signalling activity, possibly in addition to a direct tyrosine kinase
inhibition (Zhou et al, 1994). It seems tempting to speculate that
PTPase activation is also likely to be involved in the enhancement
of anti-EGFR antibody-mediated growth inhibition by GM3 in
H125 NSCLC cells. The identity of the activated PTPase(s) is
currently unknown. The SH2-domain PTPase IC has been shown
to attenuate EGFR signalling in A431 cells; however, it is unlikely
that this cytosolic PTPase is affected by exogenously added GM3.
Rather transmembrane PTPases (Charbonneau and Tonks, 1992;
Pot and Dixon, 1992) are candidate targets for GM3 action. One
could envisage GM3 effects on such PTPases either via the
membrane spanning or via the extracellular protein domains. The
observed activation by GM3 might help to identify further PTPases
involved in EGFR dephosphorylation and might present a new
regulatory principle for PTPases. Furthermore, our findings lend
support to the concept that activation of growth factor receptor-
directed PTPases could be employed as a mechanism for novel
antiproliferative agents.
ABBREVIATIONS
EGF, epidermal growth factor; EGFR, epidermal growth factor
receptor; EDTA, ethylenediamine tetraacetic acid; FCS, fetal calf
serum; DMSO, dimethyl sulphoxide; SCLC, small-cell lung carci-
noma; NSCLC, non-small-cell lung carcinoma; SDS, sodium
dodecyl sulphate; PAGE, polyacrylamide gel electrophoresis;
PTPase, protein tyrosine phosphatase.
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